For any clinical development, it will be important to identify biomarkers predictive of response, which could start with further exploration of NEDD8 and SUMO1 protein levels in tumor tissues based on the results in our PDX models, and to explore mechanisms of pevonedistat resistance. This evidence concerns the gene SUMO1 and neoplasm.